Erschienen in:
01.10.2013 | Editorial
Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch–Schönlein purpura nephritis
verfasst von:
Jean-Claude Davin, Rosanna Coppo
Erschienen in:
Pediatric Nephrology
|
Ausgabe 10/2013
Einloggen, um Zugang zu erhalten
Excerpt
The long-term prognosis of Henoch–Schönlein purpura nephritis (HSPN) depends on the severity of initial clinical symptoms and histological features [
1,
2]. The risk of evolution into a chronic kidney disease (CKD) may be as high as 50, 40 and 15 % for the combination of onset with nephrotic and nephritic syndrome, nephrotic syndrome, nephritic syndrome and/or heavy non-nephrotic proteinuria, respectively [
1]. The International Study of Kidney Disease in Children (ISKDC) classified the risk of progression on the basis of the histology severity mainly according to the extent of crescent formations. Combining three studies with a follow-up of about 6 years [
3‐
5], Haas [
2] demonstrated that 25 % of children biopsied for HSPN had severe outcomes (persistently active renal disease and/or worsened stages of CKD, including end-stage renal failure), in correlation with the ISKDC grades of renal pathology damage. These data indicate that children with HSPN have to be carefully followed, since some cases can have a catastrophic evolution. …